TY  - CONF

T1  - A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib

JO  - BRITISH JOURNAL OF HAEMATOLOGY

PY  - 2008/04/01

AU  - Jewitt K

AU  - Pilgrim H

AU  - Ward S

ED  - 

VL  - 141

SP  - 38

EP  - 38

Y2  - 2024/12/21

ER  -